ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,00%
Bitcoin
60.854,38
0,10%
Brent Oil
82,585
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) Notícias

OLMA

Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OLMA
DataHoraFonteTítuloCódigoCompanhia
08/05/202417:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202417:02GlobeNewswire Inc.Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202408:02GlobeNewswire Inc.Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
07/05/202418:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
06/05/202417:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
02/05/202417:37GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
01/05/202408:02GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in MayNASDAQ:OLMAOlema Pharmaceuticals Inc
08/04/202417:30GlobeNewswire Inc.Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202417:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202417:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202417:03GlobeNewswire Inc.Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
06/03/202409:03GlobeNewswire Inc.Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsNASDAQ:OLMAOlema Pharmaceuticals Inc
14/02/202418:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202419:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OLMAOlema Pharmaceuticals Inc
06/02/202409:01GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor ConferencesNASDAQ:OLMAOlema Pharmaceuticals Inc
31/01/202418:21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OLMAOlema Pharmaceuticals Inc
08/01/202410:12GlobeNewswire Inc.Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development CandidateNASDAQ:OLMAOlema Pharmaceuticals Inc
05/01/202419:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OLMAOlema Pharmaceuticals Inc
02/01/202418:01GlobeNewswire Inc.Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
07/12/202322:30Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
05/12/202314:27GlobeNewswire Inc.Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 StudiesNASDAQ:OLMAOlema Pharmaceuticals Inc
28/11/202319:10GlobeNewswire Inc.Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)NASDAQ:OLMAOlema Pharmaceuticals Inc
07/11/202318:02GlobeNewswire Inc.Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
01/11/202317:27GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in NovemberNASDAQ:OLMAOlema Pharmaceuticals Inc
22/10/202303:55GlobeNewswire Inc.Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for PalazestrantNASDAQ:OLMAOlema Pharmaceuticals Inc
18/10/202317:46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
17/10/202308:01GlobeNewswire Inc.Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of DirectorsNASDAQ:OLMAOlema Pharmaceuticals Inc
16/10/202308:02GlobeNewswire Inc.Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OLMA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
YDUQ3
ESTACIO PART ON
BOV
UNIP6
UNIPAR PNB
BOV
COGN3
COGNA ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados